In 'Multidisciplinary Symptom Management and Strategies for Modifying Therapy in Wilson Disease,' our panel delves into the comprehensive care models required for patients who do not achieve a full reversal of symptoms through copper-clearing therapy alone. Dr. Peter Hedera highlights the importance of the Unified Wilson’s Disease Rating Scale (UWDRS) for monitoring the emergence of new symptoms, such as tremor or balance issues, which can signal non-compliance, over-treatment, or evolving complications like myelopathy. For patients with medically refractory symptoms, the panel explores adjunctive interventions, including beta-blockers, botulinum toxin for focal dystonia, and even deep brain stimulation (DBS) for severe cases.

The discussion also addresses the management of decompensated cirrhosis and the controversial use of liver transplantation for acute neurological patients who do not respond to medication. While a transplant can restore copper homeostasis, the experts caution that it exchanges one set of challenges for another, including lifelong immunosuppression. Dr. Rima Fawaz emphasizes the critical role of non-pharmacological interventions—specifically physical, occupational, and speech therapy—to help re-educate damaged neurons as copper levels stabilize.

The final segment of the episode identifies several critical unmet needs in current Wilson disease management. These include the difficulty of monitoring pediatric patients during intercurrent illnesses, the lack of liquid formulations for chelators, and the urgent need for a commercially available, reliable assay for non-ceruloplasmin-bound copper to more accurately track compliance. The experts conclude by looking forward to upcoming trials for trientine tetrahydrochloride, which are investigating once-daily dosing and initial treatment protocols to further close these gaps in care.

Our next episode, 'Gene Therapy as an Emerging Treatment Approach in Wilson Disease,' further explores Wilson disease, highlighting the shift toward restorative treatments that aim to correct the underlying genetic defect. The panelists discuss the potential for long-term copper control through investigational gene therapies and the promise of emerging gene-editing technologies to reduce or eliminate the need for lifelong medication.